Cadila Healthcare has reported results for first quarter ended June 30, 2014.
The company’s net profit has decreased by 42.01% at Rs 197.29 crore as compared to Rs 340.22 crore for the quarter ended June 30, 2013. Its total income has decreased by 1.61% to Rs 1129.13 crore for the quarter under review from Rs 1147.64 crore for the corresponding quarter of the previous year.
On the consolidated basis, the company has reported 23.15% rise in its net profit after taxes, minority interest and share of profit / (loss) of associates at Rs 240.21 crore for the quarter as compared to Rs 195.06 crore for the same quarter in the previous year. Total income has increased by 24.91% at Rs 2060.50 crore for quarter under review as compared to Rs 1649.58 crore for the quarter ended June 30, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1668.00 |
| Dr. Reddys Lab | 1232.25 |
| Cipla | 1228.90 |
| Zydus Lifesciences | 936.35 |
| Lupin | 2328.60 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: